Jun 21 |
Sector Update: Health Care Stocks Gain in Late Afternoon
|
Jun 21 |
Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes
|
Jun 21 |
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
|
Jun 19 |
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
|
Jun 18 |
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
|
Jun 14 |
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
|
Jun 14 |
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
|
Jun 11 |
Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%
|
May 30 |
Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial
|
May 29 |
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
|